Stay updated on Bispecific Antibody MCLA-158 Clinical Trial
Sign up to get notified when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.

Latest updates to the Bispecific Antibody MCLA-158 Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5 on the page. This appears to be a minor metadata/patch update and does not change study data or user-facing content.SummaryDifference0.0%

- Check16 days agoChange DetectedThe page adds details about new expansion cohorts and dosing (RP2D of 1500 mg every 2 weeks for single-agent MCLA-158) and outlines planned combination cohorts with pembrolizumab, FOLFIRI, and FOLFOX. It also updates recruitment sites, investigators, and contact information across many locations.SummaryDifference6%

- Check23 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4 on the page, signaling a minor update to the study details page. No substantive study data or user-visible content appears to be changed.SummaryDifference0.0%

- Check52 days agoChange Detected- Page revision updated from v3.6.0 to v3.6.3, indicating a new build/version of the page rather than a change to the study content. This is a metadata-level update visible on the page.SummaryDifference0.0%

- Check66 days agoChange DetectedNew navigation/help sections such as Check who can join, Find Contact Information, How to Read a Study Record, Common Questions, and How to Join a Study were added, improving access to participation and information. The Intervention/Treatment heading formatting was updated (from 'Intervention / Treatment' to 'Intervention/Treatment'), and the footer revision label now shows Revision: v3.6.0, replacing the previous v3.5.5.SummaryDifference0.2%

- Check73 days agoChange DetectedThe page shows a new revision label, updating from v3.5.4 to v3.5.5. This indicates a new version of the page with minor edits or fixes.SummaryDifference0.0%

Stay in the know with updates to Bispecific Antibody MCLA-158 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.